

Imatinib-Resistant Mutant GIST Cell






FIG. 1

**FIG. 2**

**FIG. 3**





FIG. 4



CR (Day 28)
1/5 in zifto (2X mpk) + imatinib
2/5 in zifto (2X mpk) + regorafenib

FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10

FIG. 11A





FIG. 11B



Study was terminated due to the aggressive tumor growth
(Exceeded 3000mm3)




FIG. 12




FIG. 13

FIG. 14A




FIG. 14B







FIG. 14C

FIG. 15A





FIG. 15B






FIG. 15C




FIG. 15D

FIG. 16A
ME12098 (KIT/L567P, 7 copies)





FIG. 17A




FIG. 17B





FIG. 17C






FIG. 18




FIG. 19




FIG. 20




FIG. 21